RxDoctor Payments Data

Richard Lee, MD

Urology · New York, NYNPI 1881851202

Payments from drug & device makers

$16,412in general payments, 2019–2025

Across 23 payments — averaging $713.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Laborie Medical Technologies Corp.$15K
  • Covidien LP$350
  • Medtronic$328
  • BD$325
  • Procept Biorobotics Corporation$233
  • Boston Scientific$228
  • plus $330 from 6 others

What the payments were for

  • Consulting fees$82546%
  • Food & beverage$96954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,412 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$1,020,676
Medicare patients
1,502
Services billed
9,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron263$277,030
GemtesaVibegron169$191,726
BotoxOnabotulinumtoxina21$18,564
Tadalafil133$17,681
Tamsulosin Hcl800$16,464
Mirabegron ErMirabegron14$12,472
Finasteride676$10,927
Methenamine Hippurate99$10,435
Dutasteride223$9,292
PremarinEstrogens, Conjugated20$8,137
Silodosin57$6,898
Alfuzosin Hcl ErAlfuzosin Hcl252$6,832
Trospium Chloride ErTrospium Chloride32$4,974
Estradiol38$4,287
Potassium Citrate ErPotassium Citrate26$2,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$43$277,030263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →